Stock Analiz

BioNexus Gene Lab Corp BGLC

Medical Specialities · data as of November 13, 2026

$0.82Market cap $2M
Open the interactive analysis →

BioNexus Gene Lab Corp (BGLC) is a healthcare company listed in the US with a market value of about $2M. In the twelve months to June 30, 2026 it had revenue of $3M and net income of -$3M, a net margin of -82.4%.

Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of -8% a year, a 5-year average ROIC of -14%.

About BioNexus Gene Lab

BioNexus Gene Lab is listed in the US and classified in medical specialities. Revenue went from $212328 in 2018 to $7M in 2025, growth of about 66.2% a year. It was profitable in 3 of the last 8 years in our data. It spends 1% of revenue on research and development.

Score: 0.4 / 5

Value0/5
Future growth0/5
Track record0/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S0.8
P/B0.3
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-35.4%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)-21.9%
Revenue growth (5 yrs, per year)-8.2%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-16.3%
ROIC (5-yr avg.)-14.1%
Profitable years (of last 10)3
Years paying a dividend—

Financials, last 8 years

Fiscal yearTTM20252024202320222021202020192018
Revenue$3M$7M$10M$10M$11M$13M$11M$126955$212328
Net income-$3M-$3M-$2M-$3M-$355966$751571$1M-$246469$26454
Free cash flow-$853600-$2M-$2M-$2M$551822$5999$131059-$230090-$313701
EPS (diluted)$-0.88$-1.02$-0.09$-0.17——$0.01$0.00$0.00
Net margin-82.4%-40.2%-16.8%-26.9%-3.3%5.6%9.6%-194.1%12.5%
ROIC—-33.7%-18.4%-26.3%-3.6%11.6%15.0%-19.0%3.1%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Does BioNexus Gene Lab pay a dividend?

Not currently.

Is BioNexus Gene Lab a good stock to buy?

We do not give buy or sell advice. BioNexus Gene Lab scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.